<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339780</url>
  </required_header>
  <id_info>
    <org_study_id>113/180/2010</org_study_id>
    <nct_id>NCT01339780</nct_id>
  </id_info>
  <brief_title>Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <brief_summary>
    <textblock>
      Prostate and breast cancer continues to be the most common cancer among men and women,&#xD;
      respectively. The exact assessment of the cancer spread with detection of possible bone&#xD;
      metastasis is crucial for treatment decision. In the current study 50 patients with prostate&#xD;
      cancer and 50 patients with breast cancer at high risk for bone metastases or with know&#xD;
      metastatic disease will be studied with multiple imaging modalities. Patients will be&#xD;
      recruited from the Department of Oncology, Turku University Hospital. Planar bone&#xD;
      scintigraphy (BS), single photon emission computed tomography combined with low-dose computed&#xD;
      tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT)&#xD;
      and magnetic resonance imaging (MRI) will be performed to all patients. The primary objective&#xD;
      is to determine the diagnostic accuracy of the four imaging modalities. The secondary goal is&#xD;
      to calculate the sensitivities and specificities of the four imaging modalities on a&#xD;
      patient-to-patient and lesion-to-lesion basis. Based on the results of this study an optimal&#xD;
      imaging protocol for detection of prostate and breast cancer bone metastasis will be&#xD;
      developed and validated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with bone metastases</measure>
    <time_frame>at least 6 months follow up</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>BS, SPECT/CT, PET/CT, MRI</intervention_name>
    <description>Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.</description>
    <arm_group_label>Breast Cancer</arm_group_label>
    <arm_group_label>Prostate Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 40 to 80 years&#xD;
&#xD;
          -  Language spoken: Finnish or Swedish&#xD;
&#xD;
          -  Performance status: Karnofsky score 70 or better or WHO performance status 2 or better&#xD;
&#xD;
          -  Diagnosis: Histologically confirmed prostate or breast cancer&#xD;
&#xD;
          -  Mental status: Patients must be able to understand the meaning of the study&#xD;
&#xD;
          -  Informed consent: The patient must sign the appropriate Ethics Committee (EC) approved&#xD;
             informed consent documents in the presence of the designated staff&#xD;
&#xD;
          -  strong suspicion of first bone metastatic disease (already diagnosed metastases in&#xD;
             other organs, elevated tumor markers, destruction of bone in plain x-ray or otherwise&#xD;
             specified reasons&#xD;
&#xD;
          -  adjuvant chemo- or endocrine therapy is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing treatment for metastatic disease&#xD;
&#xD;
          -  Contraindications for MRI (cardiac pacemaker, intracranial clips etc.)&#xD;
&#xD;
          -  Infections: Patient must not have an uncontrolled serious infection&#xD;
&#xD;
          -  Claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <state>Kiinamyllynkatu 4-8</state>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Marko Seppanen</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

